Krystal Biotech
KRYS
KRYS
183 hedge funds and large institutions have $2.71B invested in Krystal Biotech in 2023 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 60 increasing their positions, 63 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
183
Holders Change
+23
Holders Change %
+14.38%
% of All Funds
2.89%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
40
Increased
60
Reduced
63
Closed
15
Calls
$26M
Puts
$20M
Net Calls
+$5.93M
Net Calls Change
+$7.01M
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$95.2M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$76.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$56.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.9M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$25M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$23.8M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$19.4M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$15.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$14.4M |
